In our ongoing mission to bring clarity to cancer care, COTA is proud to share a new addition to our growing team — Shariq Alavi. He joins COTA as a new Vice President of Life Sciences.
While we have made significant advances in recent years, we are far from providing doctors and patients with the real-world data they need to consistently make treatment decisions that result in the best outcomes, and we must do better.
The all-virtual 62nd ASH Annual Meeting & Exposition featured continued advancements in the treatment of hematologic malignancies.
In a recent article published in Forbes, COTA CEO Mike Doyle discussed the devastating impact COVID-19 has had on cancer care.
The pandemic has specifically accelerated the pace of innovation in the realm of real-world data, fueling a number of trends that we expect will carry on and pick up steam post-COVID.
COTA has a new Chief Legal Officer: healthcare and data privacy attorney Nadine Peters. She spoke with our team about her background and why she’s excited to be working at COTA based on the company’s mission & team.
Access to Over One Million Patient Data Records and Additional Funding Support Enhanced Real-World Data and Analytics Services in Oncology
Varian has invested $20M in COTA. Together, the two companies will work to empower cancer clinics with curated RWD and analytics tools.
COTA has extended its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) for an additional three years. This renewed RCA will expand on the objective to explore the applications of real-world data in oncology.
Friends of Cancer Research leads collaborative effort including COTA and nine other organizations to advance the collective understanding in applications of real-world data. New findings reveal further insights in non-small cell lung cancer (NSCLC) with a particular focus on novel treatment strategies.
Real World Talk with COTA brings together thought leaders across the industry to discuss RWD and its impact on drug development and cancer care. Meet some of our recent guests…
Leading the data and digital team at Novartis, Bruno Villetelle believes that real world data should have a real world impact on patient care. He joins the #RealWorldTalk podcast to discuss how technology and data collection are being used at all stages of treatment to improve patients’ experiences and outcomes.
A recent observational study using real world data shows promising results from using tocilizumab in patients with severe COVID-19. According to study co-author Shivam Mathura, “While these results need to be further validated through clinical trials, we are thrilled to provide early insights to those in the field as we continue to fight this pandemic.”
COTA’s Chief Medical Officer, Dr. C.K. Wang spoke with BioCentury to help further the conversation around the role of RWD in increasing racial diversity in clinical research.
Real-world data is perhaps more important now than ever, but COVID-19 has thrown patient care and data gathering in oncology into chaos.
COTA is proud to share that we have joined a diverse group of 93 companies in signing an Amicus Brief to ratify the Equal Rights Amendment. By signing this Brief, COTA joins influential companies such as Apple, Biogen, Gilead Sciences and Pfizer, in demanding gender equality in the workplace and society at large.
Along with COTA’s data analytics expertise, Hackensack Meridian Health has been pioneering some of the early work to understand COVID-19. Stuart Goldberg, MD, chief of the Division of Outcomes and Value Research at the John Theurer Cancer Center and Mike Doyle, CEO of COTA, recently spoke with Health Evolution about the findings so far, and how we continue to learn from existing patients.
The FDA’s Dr. Amy Abernethy describes how the agency and the scientific community are using real-world data to respond to COVID-19.
Around this growing interest and adoption, COTA’s chief medical officer, Dr. C.K. Wang, recently spoke with OncLive about how COTA’s Real World Analytics platform helps cancer centers correlate care patterns with outcomes.
In two recent articles, COTA CEO Mike Doyle reflects on how the pandemic is challenging leaders to be flexible and, specifically in healthcare, how data companies can be doing more.
To further explain COTA’s in-depth analysis and research methods from this ongoing work, Kathryn Tanenbaum, Senior Manager of Operations at COTA spoke with two of our data experts leading COTA’s analysis, Eric Hansen, director of analytics, and Shivam Mathura, director of product and strategy.
Interested in receiving updates on our latest posts?
